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Type 2 diabetes mellitus (T2DM) is a complex metabolic disease characterized by high blood 
glucose levels due to impaired insulin secretion or insulin resistance. Polymorphisms in the ABCC8 
gene rs1799854 are widely found to have an association with T2DM, where the ABCC8 gene encodes 
the SUR1 protein from the K-ATP channel that plays a role in insulin secretion in cells β pancreas. 
Mutations in the ABCC8 gene can cause potassium channels and insulin secretions problems that 
possibly decrease the effectiveness of the drug. Polymorphisms in some populations have been 
reported, but similar research on Solo's population has never been conducted. The purpose of this 
study is to identify the genotype of the ABCC8 gene in rs1799854 and the therapeutic outcome of 
blood glucose levels in T2DM patients. This research is cross-sectional research conducted 
prospectively at Moewardi Hospital Surakarta, Solo. Blood samples were collected from 10 T2DM 
patients who received sulfonylurea monotherapy taken through veins for genotype examination by 
DNA isolation, PCR amplification, and sequencing. Parameters of fasting blood glucose (FBG), 2-
hour postprandial blood glucose, and HbA1c are measured as therapeutic outcomes. We found the 
dominant results in a mutant homozygote (TT) 40%; while wild type (CC); and a mutant heterozygote 
(CT) was 30%. Single Nucleotide Polymorphisms (SNP) of ABCC8 gene rs1799854, found in T2DM 
patients at Moewardi Hospital Surakarta, Solo, who received sulfonylurea therapy. 
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Type 2 diabetes mellitus (T2DM) is a complex metabolic disease characterized by high blood 
glucose levels due to impaired insulin secretion and, or insulin resistance (Engwa et al., 2018). 
Diabetes is a health problem which the number of cases and prevalence continues to increase. WHO 
estimates that globally 422 million people over the age of 18 lived with diabetes in 2014 (Kemenkes, 
2018), it became a global health problem affecting more than 150 million patients worldwide (Koren 
and Koren, 2015). Based on Basic Health Research (Riskesdas, 2018), Central Java is the 12th largest 
diabetes mellitus patient in Indonesia (Riskesdas, 2018). The prevalence of type 2 DM in Central Java 
is 67.977 people, and for the city of Surakarta (Solo), the prevalence is 3.73% which is the highest 
percentage in Central Java (Kemenkes RI, 2018). The previous research on Surakarta Health Office 
data told that the prevalence of type 2 DM; has changed in the last five years. A total of 5223 cases of 
DM; in 2016, then increased to 6.579 points in 2017. The highest prevalence was reported in the 
Serengan subdistrict (14.38 in 1,000 inhabitants) (Januaristiningtyas, 2018).  
Sulfonylurea (SU); is widely used in treating T2DM with the mechanism of increasing insulin 
secretion (Klen et al., 2014). Insulin secretion is controlled by the sensitive ATP potassium channel 
(KATP). The track consists of four Kir6.2 forming subunits along with four sulfonylurea receptor 
subunits (SUR). SUR1 is a potassium channel sensitive to ATP in pancreatic beta cells (Venkatesan et 
al., 2014), and is encoded by the ATP Binding Cassette Subfamily C Member 8 (ABCC8) gene 
(Engwa et al., 2018). The mechanism of insulin release in β pancreatic cells starts when glucose 
entering the cells and resulting ATP that can bind to the KATP channel. KATP channel will close and 
cause membrane depolarization resulting in the opening of Voltage-Dependent Calcium Channel 
(VDCC), pumping Ca2+ into the cell and triggering the secretion of insulin granules (Wiyatno et al., 
2011).  
The ABCC8 gene encodes a protein that includes a member of the superfamily of ATP-binding 
cassette (ABC) transporters (Anonim, 2021). SUR1, which is encoded by the ABCC8 gene located on 
chromosome 11p15, is one of the causes of T2DM risk (Venkatesan et al., 2014). The ABCC8 gene, as 
a sulfonylurea receptor, helps regulate insulin by coding the SUR1 subunit protein from the K-ATP 
channel that plays a role in insulin secretion from pancreatic β cells. Abnormal SUR1 (ABCC8) can 
disrupt the potassium channel and insulin secretion (Zhou et al., 2019). Several polymorphism studies 
have been conducted in the ABCC8 gene, C49620T (rs1799854) in the Nigerian population (Engwa et 
al., 2018) and rs1801261 in Danish and Canadian people, were known associated with the risk of 
T2DM. However, four previous studies showed that polymorphism ABCC8 gene rs1801261 was not 
associated with T2DM risk (Zhou et al., 2019). Polymorphism in rs757110 indicates similar T2DM 
risk in Europe and Japan, but no association was observed in the Han Chinese population (Qin et al., 
2013). Another result in the South India population showed that the polymorphism ABCC8 gene 
rs1799854 (-3c→t) has no relationship with T2DM (Venkatesan et al., 2014). Research on the ABCC8 
gene in T2DM patients in the Solo population has never been reported. Moreover, the purpose of this 
study is to find out the description of the ABCC8 gene genotype and blood glucose levels as an 
outcome therapy in T2DM patients who use sulfonylurea. 
 
MATERIALS AND METHOD 
Research subjects  
The study subjects were all outpatients diagnosed with T2DM at Moewardi Hospital Surakarta, 
Solo from September 1 to October 30, 2019, who met the inclusion criteria ,i.e. > 18 years old, have 
complete data of T2DM treatment have complete data of T2DM treatment in medication records, use 
sulfonylurea monotherapy, and willing to follow this research. Patients were pregnant and using 
insulin monotherapy or other combinations of oral anti-diabetic therapy were excluded from the study. 
Blood samples taken through veins as much as 3 ml are inserted in the EDTA tube and stored at a 
temperature of -20oC. 
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The materials of this study are blood samples derived from T2DM patients, proteinase K, 
ethanol 96%, Favorprep kit (Favorgen Biotech, Taiwan), Genomic DNA mini Kit, collection tube, 
sterile microcentrifuge tube, spin columns. Materials for DNA amplification with PCR are pure DNA 
samples, PCR master Mix: Go tag green (Promega, USA), ddH2O/Nuclease-Free water (Promega, 
USA), and primary forward ABCC8 and reverse primary ABCC8 (Macrogen, Korea). Materials for 
electrophoresis and gel visualization are agarose powder (Promega, USA), GelRed/staining gel 
(Promega, USA), ladder (Geneaid, Taiwan), loading dye (Geneaid, Taiwan), buffer TAE 0.5x, and 
TAE 1x (Promega, USA).  
 
Methods 
This research is cross-sectional research with future data retrieval. Approval of the ethics 
committee of this research was obtained from Ahmad Dahlan University No. 011904040, which has 
been approved by the ethics committee of Moewardi Hospital Surakarta. Informed consent was 
obtained from all patients before this study.  
DNA is isolated and purified from 200 μl of whole blood samples using the FavorPrep Kit 
method™, and DNA extraction protocols are carried out by following manufacture instructions. 
Purified DNA is qualitatively tested with electrophoresis to observe the presence of the DNA band. 
The concentration and purity of DNA are carried out with spectrophotometry. Amplification of the 
ABCC8 gene was performed using polymerase chain reaction (PCR), which specific primer forward: 
5'-TTGGGTGCATCTGTCTGTCTGTCTTT-3' and Reverse 5'-AGCCCACCTGCCCCACGAT-3′ 
(Engwa et al., 2018).  The volume of PCR product was 25 μl consisting of a master mix of 12.5 μl Go 
tag green, ddH2O 9.5 μl, one μl primary forward and one μl reverse primer and one μl DNA template. 
PCR is carried out with the protocol: initial denaturation at 94 oC for 5 minutes, denaturation at 94 oC 
for 30 seconds, annealing at 60.5oC for 30 seconds, extension at 72oC for 40 seconds, and a final 
extension at 72oC for 4 minutes. PCR products in electrophoresis with a master mix of 5 μl PCR DNA 
samples plus five μl staining gel/GelRed (DNA dye) and six μl ladder, the solution is inserted in the 
gel well agarose 2% and running at 80 Volts for 80 minutes in a solution buffer TAE 1x. The 
observation was done with GelDoc (BLuPAD) at 122 bp and then, followed by the sequencing method. 
DNA sequencing was identified by the sanger-sequencing method. PCR products are assessed 
for sequencing tests. The sequencing (forward and reverse) data obtained was trimmed with the 
SnapGene program. Furthermore, genotypes were analyzed with the help of BioEdit software. When 
the sequencing data was obtained, the sequence forward and reverse merged (contig) then made a 
consensus. The consensus data was aligned on the NCBI data bank 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The reference/library of ABCC8 genes on the NCBI website is 
a reference for normal genes in detecting the point of mutation. The consensus of 10 samples was 
collected and aligned with the connection using the CLUSTALW approach that integrated into, with 
Bioedit program, identification of mutation diversity, observe suitability with electropherogram. 
 
Data Description 
The demographic characteristics of the patient describe descriptively include age, gender, 
ethnicity, education, occupation, therapeutic outcome (Fasting blood glucose (FBG), 2-hour 
postprandial blood glucose, and Hemoglobin A1c (HbA1c) levels), genotype, and allele frequency.  
 
 
RESULT AND DISCUSSION 
Demographic characteristics of patients  
Several 100 T2DM patients at Moewardi Hospital Surakarta were recruited for this study;ten 
patients who received sulfonylurea monotherapy were classified as research subjects, while the 
remaining 90 patients used a combination of a biguanide and sulfonylurea therapy. Demographic 
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characteristics of 10 T2DM patients showed the same gender, with an average age of 69.20±8.9 years, 
ranging from 58-80 years old. According to previous research data, T2DM increases related to age 
(Firdaushty et al.,2020), and the most extensive DM; sufferers are in the age range of 55-74 years 
which means that the age factor is substantial on the risk of DM; (Kemenkes, 2018). Patients who have 
higher education (> senior high school) were about 20% and employed (80%). Characteristic patients 
in this study are similar to the previous research that most diabetes mellitus patients are workers 
(private or government employees) and those at age more than 40 years old (Al Mansour, 2020). A 
population-based study in China reported that risk factor of diabetes mellitus includes geriatic patients, 
lower educational level, and having comorbidities (Hu et al., 2017). The average level of FBG was 219 
mg/dl, 2-hour postprandial blood glucose was 176.40 mg/dl, and the value of HbA1c groups was 8.06 
% (Table 1). The mean of DNA concentrations in all samples was 210 ng/μl with a purity index of 1.5 
to 2.3. 
 
Table 1. Demographic characteristics of patients who received sulfonylurea monotherapy 
(n=10) 
Characteristics Respondents N (%) Average ± SD 





Education < Senior High School (SD, 
SMP) 











Age   69.20±8.9 
FBG   219.0±111.58 
2-hour postprandial 
blood glucose 
  176.40±132.06 
HbA1c   8.06±1.88 
Medication  Glibenclamide 5mg  1 (10%)  
 Glimepiride  2 (20%)  
Gliquidone 30mg  4 (40%)  
Gliclazide   3 (30%)  
 
Notes: SD; Primary School, SMP Junior High School, SMA Senior High School, Diploma 1/2/3, S1/2/3: 
Bachelor 1/2/3; FBG: Fasting Blood Glucose, HbA1C Hemoglobin A1c 
 
Genotype analysis of ABCC8 rs1799854 
Insulin secretion and insulin retention related to genetic and environmental factors are the most 
common causes of T2DM (Begic et al., 2016). This current study was conducted to identify the SNP 
rs1799854 ABCC8 gene and blood glucose levels of T2DM patients who use sulphonylurea. One 
treatment in T2DM is sulfonylurea which can decrease blood glucose levels by increasing insulin 
secretion (Gumantara and Oktarlina, 2017). Sulfonylurea will bind to sulfonylurea receptors (SUR)  to 
regulate of insulin secretion from pancreatic beta cells encoded by the ABCC8 gene (Venkatesan et al., 
2014). 
Sulfonylurea is a second-line anti-diabetic that is used if the goal of first-line therapy 
(metformin) for three months, which is a decrease in HbA1c levels less than 7.5%, is not achieved 
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(ADA, 2020). However, in 10 patients who consume sulfonylurea therapy, HbA1c levels remained > 
7.5%. There are other factors that affect HbA1c levels remain high, includes adherence to taking 
medication or genetic factors due to variations in the ABCC8 gene, significantly it will disrupt the 
potassium channel and insulin regulation that causes the patient's blood glucose levels to become 
uncontrolled (Zhou et al., 2019). The quality of DNA tested with electrophoresis method, and 
quantitative using spectrophotometry. The ten samples have amplified by using PCR with a specific 
primer for the ABCC8 gene. The amplification results were identified by using electrophoresis with 
2% gel agarose and then observed with GelDoc at 122 bp (Figure 1). 
 
Figure 1. Amplification of ABCC8 gene PCR products at 122 bp (M= DNA marker 100 bp) 
Sequencing data were analyzed using SnapGene (to perform electropherogram 
trimming/cleaning with quality below 40) and Bioedit to see the mutation point. The target gene must 
match with the bank's genes, a consensus that has been collected blasted on the NCBI website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The results of genotype analysis of the ABCC8 gene with 
BioEdit (Figure 2) showed mutant homozygote points in samples no. 1, 4, 8, and 10 and mutant 
heterozygote in samples 2, 3, and 7 of the standard reference that is C allele changed to T. 
 
Figure 2. An image of  Electropherogram sequencing a point mutation in the ABCC8 gene. A= 
samples 1,4, 8, and 10 mutant homozygote mutation (CC→TT), B= samples 2,3, and 
7 mutant heterozygote mutation (CC→CT) C= sample 5,6, and 9 wild-type (CC) 
Genotype analysis of ABCC8 gene variations with PCR-sequencing method in 10 samples was 
amplified with ABCC8 target gene at 122 bp and obtained the percentage of T allele was greater than 
C allele in T2DM patients in Solo population. The distribution of CC (homozygote wild-type); and 
CT; (mutant heterozygote) genotypes has the same percentage, in contrast, the TT; genotype 
distribution (mutant homozygote) showed dominant in T2DM patients in the Solo population. The 
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dominance of TT; genotype (mutant homozygote) is comparable to the increasing prevalence of 
T2DM in Solo (Table 2). 
 
Table 2. Genotype and allele frequencies of the rs1799854 ABCC8 gene 
 Patients (N=10) 
Genotype 
CC 3 (30%) 
CT 3 (30%) 
TT 4 (40%) 
Allele 
C 0.45 (45%) 
T 0.55 (55%) 
 
The results of genotype sequencing analysis in this study showed that the distribution of 
genotype TT; (mutant homozygote) and mutant T allele frequency present a dominant percentage. 
Previous research demonstrated that ABCC8 gene polymorphism encodes SUR1 has been studied with 
many variants, including C49620T (rs1799854). It was related to T2DM in the Nigerian population, 
showing the dominant of T allele over C allele with a significant risk in T2DM (p <0.05) (Engwa et al., 
2018). However, different findings from other regions worldwide showed wild-type; C allele is usually 
more dominant in the population. Mutant homozygote TT; genotypes appear more frequently than 
wild-type; CC genotypes whereas CT; heterozygote is rarest. Genotype TT is more common in T2DM 
patients than normal individuals (Engwa et al., 2018). Similar results with this study, where the most 
dominant genotype of TT; often appears, which 40% compared to CC and CT; genotypes. In 
comparison the dominant frequency of  the T allele is 55%. 
This study found a variation point in the ABCC8 gene rs1799854, wherein the previous study, 
there were three polymorphisms of the ABCC8 gene related to sulfonylurea response, namely 
rs757110, rs1799854, and rs1799859. Polymorphism missense at rs757110 in the ABCC8 SUR-1 gene 
appears to have a higher likelihood of responding to sulfonylurea treatment (Ordelheide et al., 2018). 
Most of the research on T2DM related to variation in the ABCC8 gene focused on rs757110, 
rs1799854, rs1799859, and rs1801261. The ABCC8 gene polymorphism at rs757110 is located at the 
exons, where there is a change from base G to T (GCC → TCC), which converts amino acids from 
alanine in residues 1369 into serine (Ala1369Ser) (Haghverdizadeh et al., 2014). Another 
polymorphism, rs1799854, is located in the intron 15 exon 16-3c/t. About 17 studies on Asian and 
Caucasian populations (Sakamoto et al., 2007) proved this polymorphism, and six studies reported a 
link between this variation and the risk of T2DM and Gestational DM; in the populations of Japan 
(Yokoi et al., 2006), China, France, Turkey, and the Netherlands. For CT, genotype carriers in Japan 
and Turkey are more sensitive to the risk of T2DM, and in genotypes, TT; is more common inpatient 
populations in China and France. Meanwhile, CC genotypes are at higher risk in T2DM patients in 
Chinese and Dutch people (Zhou et al., 2009) (Haghverdizadeh et al., 2014). Polymorphism of 
rs1799859 is located in the exons area, which there is a substitution from G allele to A allele (AGG → 
AGA), However, it did not make any changes (Haghverdizadeh et al., 2014). While polymorphism of 
rs1801261 is located in the exons area, where the SNP converts the C allele into the T allele (ACC → 
ACT), but does not cause changes in amino acid threonine in residue 759 (Thr759Thr) (Venkatesan et 
al., 2014) (Haghverdizadeh et al., 2014). 
 
Genotype distribution and outcome therapy 
In patients with ABCC8 gene variations rs1799854, the therapeutic outcomes (FBG, 2-hour 
postprandial blood glucose, and HbA1c levels) were uncontrolled. However, in this study, patients 
with wild-type; genotypes also presented uncontrolled therapeutic outcomes. The outcomes defined as 
controlled if FBG <126 mg/dl, 2-hour postprandial blood glucose <200 mg/dl, HbA1c levels <6,5%. 
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However the outcomes becomes uncontrolled if FBG >126 mg/dl, 2-hour postprandial blood glucose 
>200mg/dl, HbA1c levels >6,5% (Table 3). This can be caused by many factors, such as genetic 
factors, environmental factors (lifestyle), compliance with medications as well as the right 
combination of treatments. According to previous research, the combination of metformin and 
sulfonylurea was declared more effective in controlling blood glucose levels. Moreover, other research 
conducted in China reported the effectiveness of a combination of therapies between glibenclamide 
and metformin in T2DM patients compared to glibenclamide monotherapy or metformin itself (Chien 
et al., 2007), (Gumantara and Oktarlina, 2017). The result of the ABCC8 genotypes and their 
therapeutic outcomes in a mutant homozygote (TT); showed a controlled 2-hour postprandial blood 
glucose of 75%, for FBG of 25% is controlled, while for HbA1c 100% is not controlled. Patients with 
mutant heterozygote genotypes (CT) showed 2-hour postprandial blood glucose and FBG 100% 
controlled and HbA1c 33.3% controlled. While wildtype (CC) showed 2-hour postprandial blood 
glucose and FBG 33.3% controlled and HbA1c 100% uncontrolled (Table 3). 
 
             Table 3. ABCC8 gene genotypes and patient therapy outcomes 










Controlled 1 (10%) 6 (60%) 10 (100%) 
Uncontrolled 2 (20%) 1 (10%) 
FBG Controlled 1 (10%) 4 (40%) 10 (100%) 
Uncontrolled 2 (20%) 3 (30%) 
HbA1c Controlled 0 1 (10%) 10 (100%) 
Uncontrolled 3 (30%) 6 (60%) 
Notes: FBG: Fasting Blood Glucose, HbA1C Hemoglobin A1c. 
 
The limitations of this study are the smaller number of patients. Patients who using sulfonylurea 
monotherapy are minimal, mainly using the combination of therapy with biguanide. Furthermore, it is 
necessary to measure blood glucose levels and HbA1c more than once to obtain more accurate 
therapeutic outcome data. Further studies with many participants are needed to clearly explain the 




There is a point mutation in the ABCC8 gene in the Solo population with a wild-type genotype 
of 30%, a mutant homozygote of 40%, and a mutant heterozygote of 30%. Analysis of genotypes and 
their therapeutic outcomes in a mutant homozygote (TT) showed a controlled 2-hour postprandial 
blood glucose of 75%, for FBG of 25% steady, while HbA1c 100% is not controlled. Mutant 
heterozygote genotypes (CT) showed 2-hour postprandial blood glucose and FBG 100% owned and 
HbA1c 33.3% owned. While wild-type (CC) represent 2-hour postprandial blood glucose and FBG 
33.3% controlled and HbA1c 100% uncontrolled. 
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